NCT00710762 - A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

March 31, 2014

Conditions

Ovarian Neoplasms

Interventions

DRUG

BIBF1120

DRUG

Placebo

Trial Locations (11)

1199.9.4413 Boehringer Ingelheim Investigational Site, Burton-on-Trent

1199.9.4412 Boehringer Ingelheim Investigational Site, Cambridge

1199.9.4407 Boehringer Ingelheim Investigational Site, Creigiau, Cardiff

1199.9.4410 St James's University Hospital, Leeds

1199.9.4401 Boehringer Ingelheim Investigational Site, London

1199.9.4404 Boehringer Ingelheim Investigational Site, London

1199.9.4409 Boehringer Ingelheim Investigational Site, London

1199.9.4411 Boehringer Ingelheim Investigational Site, London

1199.9.4406 Boehringer Ingelheim Investigational Site, Manchester

1199.9.4402 Boehringer Ingelheim Investigational Site, Northwood

1199.9.4405 Boehringer Ingelheim Investigational Site, Sutton